Alpha 2.0
Login Register
» Authors » Erika Van Landuyt

Erika Van Landuyt

Explore the profile of Erika Van Landuyt including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 109
Followers 0
Related Specialties
Infectious Diseases
Pharmacology
Microbiology
Top 10 Co-Authors
Erkki Lathouwers
Magda Opsomer
John Jezorwski
Joseph J Eron
Bryan Baugh
Veerle Hufkens
Simon Vanveggel
Kimberley Brown
Chloe Orkin
Sandra De Meyer
Published In
AIDS
HIV Res Clin Pract
Clin Pharmacol Drug Dev
Lancet HIV
Antiviral Res
Affiliations
Soon will be listed here.
Recent Articles
11.
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve patients with HIV-1: subgroup analyses of the phase 3 AMBER study
Rashbaum B, Spinner C, McDonald C, Mussini C, Jezorwski J, Luo D, et al.
HIV Res Clin Pract . 2019 Jul; 20(1):24-33. PMID: 31303147
: The once-daily, single-tablet regimen darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is approved for the treatment of HIV-1 infection. The 48-week efficacy and safety of D/C/F/TAF versus darunavir/cobicistat + emtricitabine/tenofovir disoproxil...
12.
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of...
Eron J, Orkin C, Cunningham D, Pulido F, Post F, De Wit S, et al.
Antiviral Res . 2019 Jul; 170:104543. PMID: 31279073
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in EMERALD (NCT02269917). Virologically-suppressed, HIV-1-positive treatment-experienced adults (previous non-darunavir virologic failure [VF] allowed) were randomized (2:1) to D/C/F/TAF or boosted...
13.
Bioequivalence of the Once-Daily Single-Tablet Regimen of Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide Compared to Combined Intake of the Separate Agents and the Effect of Food on Bioavailability
Crauwels H, Baugh B, Van Landuyt E, Vanveggel S, Hijzen A, Opsomer M
Clin Pharmacol Drug Dev . 2018 Nov; 8(4):480-491. PMID: 30412360
The effect of food on the bioavailability of the components of the once-daily, single-tablet human immunodeficiency virus (HIV) type 1 regimen containing darunavir (DRV 800 mg), cobicistat (COBI 150 mg),...
14.
A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
Eron J, Orkin C, Gallant J, Molina J, Negredo E, Antinori A, et al.
AIDS . 2018 Apr; 32(11):1431-1442. PMID: 29683855
Objectives: To investigate efficacy and safety of a single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg vs. darunavir/cobicistat plus emtricitabine/tenofovir disoproxyl fumarate (TDF) (control) in antiretroviral-treatment-naive, HIV-1-infected adults. Design: Phase-3,...
15.
Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically...
Orkin C, Molina J, Negredo E, Arribas J, Gathe J, Eron J, et al.
Lancet HIV . 2017 Oct; 5(1):e23-e34. PMID: 28993180
Background: Simplified regimens with reduced pill burden and fewer side-effects are desirable for people living with HIV. We investigated the efficacy and safety of switching to a single-tablet regimen of...